Joshua E Allen

Joshua E Allen

UNVERIFIED PROFILE

Are you Joshua E Allen?   Register this Author

Register author
Joshua E Allen

Joshua E Allen

Publications by authors named "Joshua E Allen"

Are you Joshua E Allen?   Register this Author

53Publications

1366Reads

28Profile Views

Role of Dopamine Receptors in the Anticancer Activity of ONC201.

Neoplasia 2018 01 5;20(1):80-91. Epub 2017 Dec 5.

Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2017.10.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725157PMC
January 2018

Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.

Cell Cycle 2017 Oct 10;16(19):1790-1799. Epub 2017 May 10.

a Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Department of Hematology/Oncology, Fox Chase Cancer Center , Philadelphia , PA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384101.2017.1325046DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628644PMC
October 2017

The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma.

Neoplasia 2017 Oct 30;19(10):772-780. Epub 2017 Aug 30.

Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 511436, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2017.07.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577403PMC
October 2017

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.

Oncotarget 2017 Oct 12;8(45):79298-79304. Epub 2017 May 12.

Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.17837DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668041PMC
October 2017

First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent.

PLoS One 2015 18;10(11):e0143082. Epub 2015 Nov 18.

Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0143082PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651306PMC
June 2016

Targeting TRAIL in the treatment of cancer: new developments.

Expert Opin Ther Targets 2015 25;19(9):1171-85. Epub 2015 May 25.

The University of Texas MD Anderson Cancer Center, Department of Cancer Medicine, Breast Medical Oncology , Houston, TX 77030 , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728222.2015.1049838DOI Listing
April 2016

Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated ΔNp73 Inhibition and p73 Activation.

Cancer Res 2016 04 12;76(7):1989-99. Epub 2016 Jan 12.

Penn State Hershey Cancer Institute, Department of Medicine (Hematology/Oncology), Penn State College of Medicine, Hershey, Pennsylvania. Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Hematology/Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-2430DOI Listing
April 2016

ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases.

Sci Signal 2016 Feb 16;9(415):ra18. Epub 2016 Feb 16.

Hematology/Oncology Division and Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033, USA. Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Hematology/Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scisignal.aac4374DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968406PMC
February 2016

ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.

Cell Cycle 2015 Aug 1;14(15):2422-8. Epub 2015 Jun 1.

a Division of Oncology & Stem Cell Transplant; The Children's Hospital of Philadelphia ; Philadelphia , PA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384101.2015.1054086DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614396PMC
August 2015

Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.

Mol Cancer 2015 May 1;14:99. Epub 2015 May 1.

Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, 19104, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-015-0346-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428111PMC
May 2015

Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.

Cancer Res 2015 Apr 20;75(7):1423-32. Epub 2015 Feb 20.

Penn State Hershey Cancer Institute, Department of Medicine (Hematology/Oncology), Penn State College of Medicine, Hershey, Pennsylvania. Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medical Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-3451DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537643PMC
April 2015

The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity.

Oncotarget 2014 Dec;5(24):12728-37

Hematology/Oncology Division and Penn State Hershey Cancer Institute, Penn State University, Hershey, PA, USA. Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medical Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/2890
Publisher Site
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350349PMC
http://dx.doi.org/10.18632/oncotarget.2890DOI Listing
December 2014

Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.

PLoS One 2013 26;8(9):e75414. Epub 2013 Sep 26.

Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medicine (Hematology/Oncology), Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, Pennsylvania, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0075414PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784419PMC
July 2014

Detection of circulating tumor cells in the cerebrospinal fluid of a patient with a solitary metastasis from breast cancer: A case report.

Oncol Lett 2014 Jun 24;7(6):2110-2112. Epub 2014 Mar 24.

Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medicine (Hematology/Oncology), Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2014.1993DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049668PMC
June 2014

The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype.

Cancer Biol Ther 2014 May 20;15(5):602-11. Epub 2014 Feb 20.

Department of Pharmacology; College of Pharmaceutical Sciences; Soochow University; Suzhou, PR China; Department of Pharmacology; The Penn State Hershey Cancer Institute; The Pennsylvania State University College of Medicine and Milton S. Hershey Medical Center; Hershey, PA USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/cbt.28158
Publisher Site
http://dx.doi.org/10.4161/cbt.28158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026083PMC
May 2014

COX-2 drives metastatic breast cells from brain lesions into the cerebrospinal fluid and systemic circulation.

Cancer Res 2014 May 10;74(9):2385-90. Epub 2014 Mar 10.

Authors' Affiliations: Department of Medicine, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, (Hematology/Oncology), Penn State Hershey Cancer Institute, Penn State College of Medicine; Department of Neurological Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania; and American Cancer Society, Atlanta, Georgia.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-13-2660DOI Listing
May 2014

Methylseleninic acid elevates REDD1 and inhibits prostate cancer cell growth despite AKT activation and mTOR dysregulation in hypoxia.

Cancer Med 2014 Apr 7;3(2):252-64. Epub 2014 Feb 7.

Department of Biochemistry and Molecular Biology, Penn State College of Medicine, Penn State Hershey Cancer Institute, Hershey, Pennsylvania.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cam4.198
Publisher Site
http://dx.doi.org/10.1002/cam4.198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987075PMC
April 2014

The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer.

PLoS One 2013 12;8(3):e59380. Epub 2013 Mar 12.

Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medicine (Hematology/Oncology), Penn State Hershey Cancer Institute, Hershey, PA, USA.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0059380PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595267PMC
September 2013

Emerging molecular therapies for the treatment of acute lymphoblastic leukemia.

Adv Exp Med Biol 2013 ;779:341-58

Department of Medicine (Hematology/Oncology), Penn State Hershey Cancer Institute and Penn State Hershey Medical Center, Hershey, PA 17033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4614-6176-0_16DOI Listing
April 2013

Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.

Sci Transl Med 2013 Feb;5(171):171ra17

Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medicine-Hematology/Oncology, Penn State Hershey Cancer Institute, Hershey, PA 17033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3004828DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535715PMC
February 2013

Calcein-effluxing human colon cancer cells are enriched for self-renewal capacity and depend on β-catenin.

Oncotarget 2013 Feb;4(2):184-91

Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medicine (Hematology/ Oncology), Penn State Hershey Cancer Institute.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/883
Publisher Site
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712565PMC
http://dx.doi.org/10.18632/oncotarget.883DOI Listing
February 2013

Therapeutic targeting of the p53 pathway in cancer stem cells.

Expert Opin Ther Targets 2012 Dec 24;16(12):1161-74. Epub 2012 Sep 24.

Penn State Hershey Cancer Institute, Penn State College of Medicine, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medicine (Hematology/Oncology), 500 University Drive, Room T4423, Hershey, PA 17033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728222.2012.726985DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650610PMC
December 2012

Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9.

Mol Cancer Ther 2012 Nov 10;11(11):2321-30. Epub 2012 Sep 10.

Penn State Milton S. Hershey Medical Center and Cancer Institute, 500 University Drive CH046, Office T4419, Hershey, PA 17033, USA.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-12
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-12-0578DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502072PMC
November 2012

Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes.

Mol Cancer Ther 2012 Oct 16;11(10):2087-95. Epub 2012 Jul 16.

Penn State Milton S. Hershey Medical Center and Cancer Institute, 500 University Drive CH046, Office T4423 Hershey, PA 17033, USA.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/content/early/2012/07/13/1535-71
Web Search
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-12
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-12-0366DOI Listing
October 2012

Regulation of the human TRAIL gene.

Cancer Biol Ther 2012 Oct 15;13(12):1143-51. Epub 2012 Aug 15.

Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medicine (Hematology/Oncology), Penn State Hershey Cancer Institute, Hershey, PA, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/cbt.21354
Publisher Site
http://dx.doi.org/10.4161/cbt.21354DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469471PMC
October 2012

Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation.

Cell Cycle 2012 Sep 16;11(17):3312-23. Epub 2012 Aug 16.

Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medicine (Hematology/Oncology), Penn State Hershey Cancer Institute, Penn State Hershey Medical Center, Penn State College of Medicine, Hershey, PA, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/cc.21670
Publisher Site
http://dx.doi.org/10.4161/cc.21670DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466529PMC
September 2012

Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases.

Oncotarget 2011 Oct;2(10):752-60

Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medicine (Hematology/Oncology), Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248154PMC
http://dx.doi.org/10.18632/oncotarget.336DOI Listing
October 2011

Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.

Cancer Biol Ther 2011 Aug 1;12(3):229-38. Epub 2011 Aug 1.

Penn State Hershey Cancer Institute, Penn State Hershey Medical Center, Hershey, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.12.3.17033DOI Listing
August 2011

Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer.

Cancer Biol Ther 2011 Aug 1;12(3):239-51. Epub 2011 Aug 1.

Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Hematology/Oncology Division, Penn State Hershey Cancer Institute, Penn State Hershey Medical Center, Hershey, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.12.3.17034DOI Listing
August 2011

Circulating Tumor Cells and Colorectal Cancer.

Curr Colorectal Cancer Rep 2010 Oct;6(4):212-220

Penn State Hershey Cancer Institute, 500 University Drive, T3315, Hershey, PA 17033, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11888-010-0069-7
Publisher Site
http://dx.doi.org/10.1007/s11888-010-0069-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2946252PMC
October 2010

Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes.

Cancer Biol Ther 2009 Nov 27;8(22):2194-205. Epub 2009 Nov 27.

Laboratory of Molecular Oncology and Cell Cycle Regulation, Departments of Medicine (Hematology/Oncology), Genetics and Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2975270PMC
http://dx.doi.org/10.4161/cbt.8.22.10450DOI Listing
November 2009